Generic Cerdelga Availability

Last updated on Jul 9, 2025.

Cerdelga is a brand name of eliglustat, approved by the FDA in the following formulation(s):

CERDELGA (eliglustat tartrate - capsule;oral)

• Manufacturer: GENZYME CORP
  Approval date: August 19, 2014
  Strength(s): EQ 84MG BASE ^{[RLD] [AB]}

Is there a generic version of Cerdelga available?

A generic version of Cerdelga has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Cerdelga and have been approved by the FDA:

eliglustat tartrate capsule;oral

• Manufacturer: AIZANT
  Approval date: September 8, 2021
  Strength(s): EQ 84MG BASE ^[AB]
• Manufacturer: CIPLA
  Approval date: December 10, 2024
  Strength(s): EQ 84MG BASE ^[AB]
• Manufacturer: UPSHER SMITH LABS
  Approval date: May 2, 2023
  Strength(s): EQ 84MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cerdelga. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Methods for treating Gaucher disease
  Patent 10,888,544
  Issued: January 12, 2021
  Inventor(s): Li Jing & Peterschmitt M. Judith & Kanamaluru Vanaja & Chen Jun & Gaemers Sebastiaan J. M. & Rudin Dan
  Assignee(s): GENZYME CORPORATION
  

  Methods for treating Gaucher disease in patients with renal or hepatic impairment.

  Patent expiration dates:

  • December 13, 2038
    
    ✓ 
    Patent use: LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MILD HEPATIC IMPAIRMENT AND ARE CONCURRENTLY TAKING A STRONG OR MODERATE CYP3A INHIBITOR
  • December 13, 2038
    
    ✓ 
    Patent use: LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MODERATE TO SEVERE RENAL IMPAIRMENT
• Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
  Patent 10,888,547
  Issued: January 12, 2021
  Inventor(s): Peterschmitt Judith
  Assignee(s): Genzyme Corporation
  

  The hemitartrate salt of a compound represented by the following structural formula:

  Patent expiration dates:

  • January 31, 2031
    
    ✓ 
    Patent use: LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 POOR METABOLIZERS WITH 84 MG ONCE DAILY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE)
  • January 31, 2031
    
    ✓ 
    Patent use: LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE OR INTERMEDIATE METABOLIZERS WITH 84 MG TWICE PER DAY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE TWICE PER DAY)
• Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
  Patent 11,458,119
  Issued: October 4, 2022
  Inventor(s): Liu; Hanlan et al.
  Assignee(s): GENZYME CORPORATION (Cambridge, MA)
  

  The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described. ##STR00001##

  Patent expiration dates:

  • November 24, 2030
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
  Patent 7,196,205
  Issued: March 27, 2007
  Inventor(s): Siegel; Craig et al.
  Assignee(s): The Regents of the University of Michigan (Ann Arbor, MI); Genzyme Corporation (Cambridge, MA)
  

  Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.

  Patent expiration dates:

  • June 26, 2026
    
    ✓ 
    Drug substance

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer